Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Rhythm Pharmaceuticals Inc (RYTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,041,277
  • Shares Outstanding, K 34,411
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,060 K
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.69
  • Number of Estimates 2
  • High Estimate -0.54
  • Low Estimate -0.83
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.52 +20.10%
on 03/07/19
31.56 -2.87%
on 03/21/19
+3.15 (+11.45%)
since 02/21/19
3-Month
23.44 +30.76%
on 12/24/18
31.56 -2.87%
on 03/21/19
+6.14 (+25.05%)
since 12/21/18
52-Week
16.80 +82.44%
on 04/02/18
37.23 -17.67%
on 06/27/18
+7.70 (+33.55%)
since 03/21/18

Most Recent Stories

More News
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today reported...

RYTM : 30.65 (+1.29%)
Rhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

RYTM : 30.65 (+1.29%)
Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Alexion Pharmaceuticals,...

AFI : 14.20 (+4.72%)
RYAM : 13.62 (+3.73%)
RYTM : 30.65 (+1.29%)
PLUG : 2.54 (-3.05%)
ALXN : 134.21 (+1.94%)
SXC : 9.26 (+2.21%)
Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference

- Updated clinical data from Phase 2 basket studies evaluating setmelanotide in Bardet-Biedl Syndrome (BBS) show continued weight loss for additional two patients at longer-term follow-up -

JPM : 102.87 (-1.58%)
RYTM : 30.65 (+1.29%)
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

RYTM : 30.65 (+1.29%)
Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

RYTM : 30.65 (+1.29%)
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alstrom Syndrome at ObesityWeek 2018

Company continues on track to initiate combined Phase 3 clinical trial in Alstrom Syndrome and Bardet-Biedl Syndrome before end of 2018

RYTM : 30.65 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade RYTM with:

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

2nd Resistance Point 32.28
1st Resistance Point 31.47
Last Price 30.65
1st Support Level 29.92
2nd Support Level 29.19

See More

52-Week High 37.23
Last Price 30.65
Fibonacci 61.8% 29.43
Fibonacci 50% 27.01
Fibonacci 38.2% 24.60
52-Week Low 16.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar